Label schedules
Tirzepatide dose schedule
Tirzepatide is sold as Mounjaro and Zepbound, and both labels describe once-weekly injections. Their shared active ingredient does not erase differences in indications or in the wording around escalation. This dose schedule places the adult label references together while keeping their conditions visible. It also distinguishes the prescribed amount in milligrams from any volume calculation used for a separately supplied vial. Mounjaro labelZepbound label
Sources checked
Zepbound: initiation, escalation, maintenance
Zepbound begins with 2.5 mg weekly for four weeks, followed by 5 mg weekly. Further changes use 2.5 mg increments after at least four weeks at the current amount. In weight management, maintenance doses are 5, 10, or 15 mg weekly. In obstructive sleep apnea, the label lists 10 or 15 mg weekly. The 2.5 mg initiation amount is not a maintenance dose. Zepbound label
The longer a reference table becomes, the easier it is to read it as a mandatory ladder. That is why this table describes later stages as conditional instead of assigning every reader a fixed week for reaching 15 mg. It retains the difference between a minimum interval, a prescribed change, and an ongoing maintenance phase. Those are separate pieces of information.
| Timing | Amount | Label context |
|---|---|---|
| 1–4 | 2.5 mg weekly | Initiation |
| 5 onward | 5 mg weekly | After the initial four weeks |
| Later, if prescribed | 7.5, 10, 12.5, then 15 mg weekly | At least four weeks at each current dose; 2.5 mg steps |
Mounjaro: read the current conditional wording
The current Mounjaro label starts at 2.5 mg weekly and describes increases of 2.5 mg after at least four weeks at the current dose when additional glycemic control is needed. The maximum weekly amount is 15 mg in adults. Its pediatric maximum is different, so the table below is explicitly limited to the adult reference. Product-specific instructions remain important even when the milligram strengths overlap. Mounjaro label
| Timing | Amount or increment | Condition |
|---|---|---|
| Starting phase | 2.5 mg weekly | Current label initial amount |
| After at least 4 weeks at current dose | Increase by 2.5 mg if additional glycemic control is needed | Prescriber-directed timing |
| Later stages, if prescribed | 5, 7.5, 10, 12.5, 15 mg weekly | Adult maximum: 15 mg weekly |
Why units cannot be added to a generic schedule
A dose expressed in milligrams does not imply one universal syringe marking. For arithmetic purposes, a 10 mg vial in a final volume of 2 mL has a concentration of 5 mg/mL. A 10 mg vial in 4 mL has a concentration of 2.5 mg/mL. The same 0.20 mL volume would contain 1 mg in the first example and 0.5 mg in the second. Arithmetic
These examples are numerical illustrations, not preparation instructions or approved-product concentrations. A prescribed pen or branded vial follows its own label. The units reference and tirzepatide calculator keep the calculation separate from the choice of a clinical dose. A result can be arithmetically correct while its inputs describe the wrong container, which is why identifying the actual concentration comes before interpreting the output. Arithmetic
Represent the plan without rewriting the history
PinPoint supports titration phases for step-ups and step-downs, along with weekly reminders, a calendar, and backfilled dose entries. Injection logs can include the compound, amount, site, and pain level. That structure can preserve the history of an earlier phase while the entered plan reflects a later one. Notes and side-effect severity entries offer space for dated observations alongside the injection record. App features
The supply forecast concerns remaining vials or pens. The modeled-level curve concerns a mathematical pattern based on published half-life data. Neither feature decides a maintenance amount or confirms an individual blood level. Keeping the source schedule, personal prescription, actual dose history, and app model distinct makes a review of the record easier to follow. App features
Useful distinctions
Questions
What is the shortest interval between escalation steps in these references?
The labels describe at least four weeks at the current dose before later increases. Zepbound also specifies its initial four-week 2.5 mg stage. Minimum intervals do not require a change at the first eligible date. Zepbound labelMounjaro label
Are 20 units a tirzepatide dose?
Twenty U-100 units is 0.20 mL. The milligram amount depends on the solution concentration, so the syringe marking alone cannot answer the dose question. Arithmetic
Your record, together
Keep the details attached to the date.
Dose history, reminders, daily notes, and the context you choose to record. PinPoint app features.
Get PinPoint on the App StoreSources & scope
Label facts link to the full prescribing information. Product claims use the supplied PinPoint app description. Numerical examples show their assumptions and arithmetic.
- PinPoint feature description
Only feature claims verified against the supplied description. No prices, clinical recommendations or inferred tablet inventory.
- Arithmetic shown on this page
Numerical derivations, dimensional distinctions and declared assumptions only.
Concentration mg/mL = total mg / final mL. U-100 volume mL = units / 100. Contained mg = concentration * volume. These are hypothetical examples, not preparation instructions or clinical amounts.
- How to read this reference
Editorial organization, explicit scope limits, and interpretation of the cited label or app evidence. No additional medical facts.
- Mounjaro prescribing information
2 (schedule/administration), 3 (presentations), 6.1–6.2 (adverse reactions), 14 (study identity), Medication Guide and Instructions for Use. DailyMed set ID:
d2d7da5d-ad07-4228-955f-cf7e355c8cc0. - Zepbound prescribing information
2 (schedule/administration), 3 (presentations), 6.1–6.2 (adverse reactions), 14 (study identity), Medication Guide and Instructions for Use. DailyMed set ID:
487cd7e7-434c-4925-99fa-aa80b1cc776b.